Skip to content

Cancer Health Center

Font Size

Chronic Myelogenous Leukemia Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (08 / 02 / 2013)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Chronic Myelogenous Leukemia

Recommended Related to Cancer

I Had the Cancer No One Talks About

By Darci Picoult It began with a bump. The size of a pinhead. Innocuous. An innocuous little pinhead of a bump on my vulva. Given that my gynecologist said the bump was probably nothing, I laughed it off. Which, in turn, made my bump mad. Very mad. It wanted my attention. And so it grew. I smeared it in medicine. It grew more. More medicine. More growth. Hanukkah came. Then Christmas. A war raged between us. I went to battle in the middle of the night with salt baths and creams. Prayed for its departure...

Read the I Had the Cancer No One Talks About article > >

Added Jabbour et al. as reference 10.

Stage Information for Chronic Myelogenous Leukemia

Added Jabbour et al. as reference 1.

Added Fabarius et al. as reference 4.

Treatment Option Overview

Added Jabbour et al. as reference 1.

Revised text to state that in a randomized, prospective study of 846 patients comparing nilotinib with imatinib, the rate of major molecular response at 24 months was 71% and 67% for two-dose schedules of nilotinib and 44% for imatinib. Also added that progression to accelerated-phase chronic myelogenous leukemia (CML) or blast-crisis occurred in 17 patients on imatinib, but this progression only occurred in two patients and five patients, respectively, on two-dose schedules of nilotinib (cited 2011 Kantarjian et al. as reference 7).

Revised text to state that the rate of major molecular response at 24 months was 64% for dasatinib and 46% for imatinib. Also added that progression to accelerated-phase CML or blast-crisis phase occurred in 13 patients on imatinib and in six patients on dasatinib, which is not statistically different (cited 2012 Kantarjian et al. as reference 8 and level of evidence 1iiDiv).

Chronic-Phase Chronic Myelogenous Leukemia

Revised text to state that in a randomized, prospective study of 846 patients comparing nilotinib with imatinib, the rate of major molecular response at 24 months was 71% and 67% for two-dose schedules of nilotinib and 44% for imatinib. Also added that progression to accelerated-phase CML or blast crisis occurred in 17 patients on imatinib, but this progression only occurred in two patients and five patients, respectively, on two-dose schedules of nilotinib (cited 2011 Kantarjian et al. as reference 7).

Revised text to state that the rate of major molecular response at 24 months was 64% for dasatinib and 46% for imatinib. Also added that progression to accelerated-phase CML or blast-crisis phase occurred in 13 patients on imatinib and in six patients on dasatinib, which is not statistically different (cited 2012 Kantarjian et al. as reference 8 and level of evidence 1iiDiv).

    1|2
    Next Article:

    Today on WebMD

    Colorectal cancer cells
    New! I AM Not Cancer Facebook Group
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Ovarian cancer illustration
    Real Cancer Perspectives
     
    Jennifer Goodman Linn self-portrait
    Blog
    what is your cancer risk
    HEALTH CHECK
     
    colorectal cancer treatment advances
    Video
    breast cancer overview slideshow
    SLIDESHOW
     
    prostate cancer overview
    SLIDESHOW
    lung cancer overview slideshow
    SLIDESHOW
     
    ovarian cancer overview slideshow
    SLIDESHOW
    Actor Michael Douglas
    Article